# Imatinib Mesylate in Combination With Pembrolizumab in Patients With Melanoma

> **NCT04546074** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Keio University** · enrollment: 22 (estimated)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** Pembrolizumab and Imatinib mesylate
- **DRUG:** Pembrolizumab and Imatinib mesylate

## Key facts

- **NCT ID:** NCT04546074
- **Lead sponsor:** Keio University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-09-14
- **Primary completion:** 2024-10-31
- **Final completion:** 2025-10-31
- **Target enrollment:** 22 (ESTIMATED)
- **Last updated:** 2023-10-03

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04546074

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04546074, "Imatinib Mesylate in Combination With Pembrolizumab in Patients With Melanoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04546074. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*